

Department of Health and Human Services Maine Center for Disease Control and Prevention 286 Water Street 11 State House Station Augusta, Maine 04333-0011 Tel.: (207) 287-8016; Fax: (207) 287-9058

June 2013

Volume 1, Issue 9

TTY Users: Dial 711 (Maine Relay)

New Prevnar 13 Recommendations

On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar) for adults aged \geq 19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants.

The Maine Immunization Program (MIP) supplies vaccine at no charge to children 0 through 18 years old, however we want providers to be aware of all important vaccine updates regardless of the age indication.

ACIP recommendations for PCV13 and PPSV23 Use:

ACIP recommends that adults aged ≥ 19 years with any of the above conditions, who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first, followed by a dose of PPSV23 at least 8 weeks later. Subsequent doses of PPSV23 should follow current PPSV23 recommendation for adults at high risk. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19-64 years with functional or anatomic asplenia and for persons with immunocompromising conditions. Additionally, those who received PPSV23 before 65 years for any indication should receive another dose of the vaccine at age 65 years, or later if at least 5 years have elapsed since their previous PPSV23 dose.

Previous vaccination with PPSV23. Adults aged \geq 19 years with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, who previously have received \geq 1 doses of PPSV23 should be given a PCV13 dose \geq year after the last PPSV23 dose was received. For those who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23

Morbidity and Mortality Weekly Report - ACIP Recommendations for PCV13 and PPSV23 Use: www.cdc.gov/mmwr/pdf/wk/mm6140.pdf

Recommendations for Pneumococcal Vaccine Use in Children and Teens, please visit: www.immunize.org/catg.d/p2016.pdf

Please remember that the MIP only provides vaccine to children ages 0 through 18 years old and this information is for your guidance only.

If you have any questions, please contact the Maine Immunization Program at:

Phone: (207) 287-3746 or (800) 867-4775

Email : www.ImmunizeME.DHHS@maine.gov

